Thermo Fisher Scientific (NYSE:TMO) has received
the CE mark in the European Union for its diagnostic test to detect
nucleic acid from SARS-CoV-2, the virus that causes COVID-19.
The company’s test, which uses Applied Biosystems
TaqPath Assay and real-time PCR technology, is designed to provide
patient results within four hours of a sample being received by a lab.
Thermo Fisher’s test complies with the European Union’s In vitro Diagnostic Directive.
TMO’s diagnostic test has received the designated approvals in the U.S., Canada, Singapore, India, Australia and New Zealand.
https://seekingalpha.com/news/3555348-thermo-fisher-nabs-ce-mark-in-europe-for-covidminus-19-diagnostic-test
No comments:
Post a Comment
Note: Only a member of this blog may post a comment.